Yipin Hong's subsidiary, Guangzhou Yipin Hong Pharmaceutical Co., Ltd., has received acceptance from the National Medical Products Administration for its clinical trial application for the innovative drug APH03867. This marks a significant step in the drug's development process. Separately, Shanghai Yancheng Trading Co., Ltd. saw changes in its leadership, with Kelly Zong appointed as the legal representative and manager, and Zhejiang Hongyi Holding Group Co., Ltd. as the sole shareholder. AI
RANK_REASON The cluster reports on a drug candidate receiving regulatory acceptance for clinical trials, which falls under research and development milestones. [lever_c_demoted from research: ic=1 ai=0.1]
- APH03867
- Guangzhou Yipin Hong Pharmaceutical Co., Ltd.
- Kelly Zong
- National Medical Products Administration
- Shanghai Yancheng Trading Co., Ltd.
- Yipin Hong
- Zhejiang Hongyi Holding Group Co., Ltd.
AI-generated summary · Google Gemini · from 1 sources. How we write summaries →